Bayer to offload animal health business to Elanco for £6.27bn
As per the terms of the deal, Bayer will receive $5.3bn (£4.37bn) in cash and will be issued $2.3bn (£1.9bn) worth shares in the US-based Elanco Animal Health.
The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung
The study has achieved its co-primary endpoint of investigator-assessed progression-free survival (PFS). Roche’s combination of Tecentriq plus platinum-based chemotherapy demonstrated a statistically significant reduction in the risk of
The late-stage trial assessed the efficacy and safety of Kisqali plus fulvestrant combination in postmenopausal women having hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or